FISHAWACK-HEALTH
8.4.2020 21:17:05 CEST | Business Wire | Press release
Fishawack Health , the global healthcare communications agency, announces the acquisition of Skysis , a boutique consulting firm providing integrated market access and commercial strategy solutions based in the US.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200408005692/en/
Skysis expertise bolsters Fishawack Health’s impressive consulting capabilities. The company brings with it the ability to connect interdependencies across healthcare professional (HCP), payer, channel, and patient stakeholders. It is the first acquisition with Fishawack Health’s new investor, Bridgepoint.
Oliver Dennis , Fishawack Health co-founder and CEO, said: “In partnering with Bridgepoint, we have made a step-change in our ambition. We’re delighted today to add Skysis to the group. They bring strategy and market access across the entire commercial life cycle, making them an important addition to our strategic consulting capabilities.”
Fred Bassett , Head of Consulting for Fishawack Health, added: “Skysis provides strategy and execution across every stage of the commercial life cycle. The company’s expertise bolsters Fishawack Health’s strong strategic consulting team, which includes analysts, researchers, commercial consultants, market access and customer experience specialists, and boasts a network of Physician Expert Partnerships.”
Providing further detail, Dan Twibell , Managing Director of Skysis, explained: “We wanted to partner with a group that could help us scale our business, offer more solutions to our clients and that our team would be excited to join.”
Dawn Rich , Managing Director of Skysis, said: “Our team is thrilled to be joining Fishawack Health. Our core capabilities match perfectly with the key services of the wider consulting capability.”
Fairmount Partners, a leading investment bank focused on pharmaceutical services businesses, introduced the parties identifying that Skysis’ four core practice areas – market access, new product planning /launch excellence, market insights, brand management and engagement – were a perfect match with Fishawack Health’s capabilities.
Established in 2001, Fishawack Health has become one of the largest independent healthcare communications organisations in the world. It has 14 offices across Europe and the US, and a highly skilled workforce of 850 employees. It serves more than 100 customers across 300 different drug compounds, including the top 20 global pharmaceutical companies and a range of innovative biotech and medical device companies.
Its three areas of specialism – strategic consulting and market access, medical communications, and commercial and creative execution – are underpinned by shared world-class resources. This includes digital expertise, insight, data analytics and visualisation, and media and production capabilities. These capabilities work independently or combine seamlessly as one unit, complete with teams tailored to the client’s individual needs and challenges.
Fishawack Health’s strategic and scientific focus makes it ideally placed to solve complex brand, portfolio, and enterprise-level challenges for its clients.
With experience across every major therapeutic category, Fishawack Health understands what it takes to improve patient outcomes and drive business success for its clients. The company will continue to add new capabilities designed to solve its clients’ critical medical and commercial challenges in an integrated and seamless way.
About Fishawack Health
Fishawack Health is an independent, full-service, global healthcare communications group with over 850 medical experts, marketing professionals, and strategic specialists. The organisation has three areas of specialism that work independently or as a single united team – strategic consulting and market access, medical communications, and commercial/creative execution.
About Skysis
Skysis is a boutique consulting firm that provides integrated commercial solutions to the biopharmaceutical industry. The organisation leverages their deep industry experience to generate insights and approaches that address their clients’ unique commercial needs.
Advisers involved in this transaction included:
KPMG Manchester acted on behalf of Fishawack Health for corporate finance and financial & tax due diligence; Addleshaw Goddard, Manchester and Sheppard Mullin, San Diego provided legal support. KPMG, Fairmount Partners, a leading investment bank focused on pharmaceutical services businesses, introduced the parties and acted as financial advisor to Skysis. Ulber & Berne LLP provided legal support.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200408005692/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SES’s O3b mPOWER Satellite Network to Connect Seven New Petrobras FPSOs5.5.2026 08:50:00 CEST | Press release
New FPSOs will enter into operation in Brazil between 2026 and 2030 to meet the energy sector’s growing demand SES, a leading space solutions company, will provide service on its high-capacity medium-Earth orbit (MEO) satellite network, O3b mPOWER, to Petrobras, the Brazilian state-owned oil company, to connect multiple new Floating Production, Storage and Offloading systems (FPSOs). The projects will go into operation in the coming years, expanding Petrobras’ oil and gas production capacity to meet national energy needs and contribute to global oil markets. FPSOs are modern and efficient oil production platforms, responsible for processing, collecting, storing, and transferring oil to shuttle tankers, directly from subsea wells in deepwater fields. FPSOs offer the flexibility, capacity, and operational resilience needed to sustain large-scale offshore production in remote and challenging environments. Brazil is home to the majority of the offshore projects under development worldwide,
Regnology Completes Acquisition of Moody’s Regulatory Reporting & Asset and Liability Management (ALM) Solutions5.5.2026 08:00:00 CEST | Press release
Transaction strengthens Regnology’s global position as the go‑to partner for AI‑powered regulatory reporting, risk, and ALM Regnology, a global provider at the intersection of regulatory, risk, finance and supervisory technology, today announced the completion of its acquisition of Moody’s Regulatory Reporting & ALM Solutions business. The transaction expands Regnology’s solution portfolio with Moody’s comprehensive capabilities covering Basel III compliance, IFRS 9 impairment, large‑bank asset and liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting. The transaction closes at a pivotal inflection point. Financial institutions face intensifying regulatory scrutiny, growing data complexity, and rising expectations for governance and auditability, while advances in artificial intelligence are creating new opportunities to modernize control frameworks and operating models. Regnology is responding by accelerating its Straight-Thro
AB InBev Reports First Quarter 2026 Results5.5.2026 07:02:00 CEST | Press release
Solid top- and bottom-line performance: Revenue up by 5.8%, Beer volume growth of 1.2% and a 20.8% Underlying EPS increase Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504526109/en/ Regulated information1 “Cheers to beer - the strength of the category and the consistent execution of our consumer-centric strategy drove continued momentum across our footprint. We are investing behind our megabrands and innovations to lead and grow the category. With strong execution by our teams and major moments of celebration ahead, we are well positioned for 2026.” – Michel Doukeris, CEO, AB InBev Revenue +5.8% Revenue increased by 5.8% with revenue per hl growth of 4.5%. Reported revenue increased by 12.0% to 15 267 million USD, positively impacted by currency translation. 8.2% increase in combined revenues of megabrands, led by Corona, which grew by 16% outside of its
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom